Researchers / academia

Parkinson’s Gets Fast Track, Not Fast Proof

Antidepressant Trials Still Leave People Out

ALS Biomarkers Are Entering the Approval Fight

GLP-1 drugs can reduce adolescent obesity. Who will pay for years of treatment?

Boehringer Ingelheim is adding a third target to obesity treatment.

Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.

The weight came back. Some visceral fat did not. Obesity care may be measuring the wrong outcome

A Breast-Cancer Warning Is Hiding in Aggregated Data

Prevention Is Now Alzheimer’s Hardest Trial
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
